FBLG Q4 2024 Earnings — FibroBiologics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

FBLGFibroBiologics, Inc. Common Stock

$17M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$4M

Net Income

-$3M

EPS (Diluted)

$-0.09

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$544,000

Balance Sheet

Total Assets

$16M

Total Liabilities

$14M

Stockholders' Equity

$3M

Cash & Equivalents

$14M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$4M	-$2M	-49.7%
Net Income	-$3M	-$10M	+68.1%